NGL Fine Chem's Q3 financial report shows mixed results, with concerns over profit and cash flow.

NGL Fine Chem, a smallcap pharmaceutical company, recently announced its financial results for the quarter ending September 2024. The company's stock has been given a 'Sell' call by MarketsMOJO.

According to the financial report, NGL Fine Chem's net sales for the half-yearly period have shown a growth of 21.83% year on year, reaching Rs 184.23 crore. This indicates a positive trend in the company's sales performance in the near term.

However, the company's profit before tax (PBT) less other income has fallen by 23.41% year on year, reaching Rs 8.21 crore. This is a concerning trend in the near term for NGL Fine Chem.

Additionally, the company's operating cash flow for the year has been the lowest in the last three years, at Rs 11.14 crore. This suggests a decline in the company's cash revenues from business operations.

Furthermore, NGL Fine Chem's non-operating income for the quarter is 38.41% of its PBT. This indicates that a significant portion of the company's income is coming from non-business activities, which may not be a sustainable business model.

Overall, NGL Fine Chem's financial performance for the quarter has been flat, with a score of -2 compared to 2 in the previous quarter. Investors should carefully consider these factors before making any investment decisions.